XML 27 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Loss Per Share
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Loss Per Share Loss Per Share
 
Basic loss per share is computed by dividing net loss attributable to American Renal Associates Holdings, Inc., net of the change in the difference between the redemption value and estimated fair value for accounting purposes of related noncontrolling interest put provisions, by the weighted-average number of common shares outstanding during the applicable period, less unvested restricted stock. Diluted loss per share is computed using the weighted-average number of common shares outstanding during the applicable period, plus the dilutive effect of outstanding options, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. Certain shares related to some of the Company’s outstanding stock options were excluded from the computation of diluted earnings per share because they were anti-dilutive in the periods presented, but could be dilutive in the future.
 
Year Ended December 31,
 
2019
 
2018
 
2017
Basic and Diluted
  

 
  

 
  

Net loss attributable to American Renal Associates Holdings, Inc.
$
(13,790
)
 
$
(28,767
)
 
$
(4,597
)
Change in the difference between the redemption values and estimated fair values for accounting purposes of the related noncontrolling interests
(7,999
)
 
(2,566
)
 
(11,503
)
Net loss attributable to common shareholders
(21,789
)
 
(31,333
)
 
(16,100
)
Weighted‑average common shares outstanding
32,274,570

 
31,965,844

 
31,081,824

Weighted‑average common shares outstanding, assuming dilution
32,274,570

 
31,965,844

 
31,081,824

Loss per share, basic and diluted
$
(0.68
)
 
$
(0.98
)
 
$
(0.52
)
Outstanding options and restricted stock excluded as impact would be antidilutive
2,986,656

 
3,442,048

 
1,894,340